PLANO, TX--(Marketwired - Apr 7, 2014) - Polaris International Holdings, Inc. (OTC Pink: PIHN) (PINKSHEETS: PIHN) is excited to announce its medical division, ProCannas, has begun development of a unique and proprietary transdermal patch capable of delivering cannabinoids directly through the skin. This hallmark solution is intended to address a significant, unmet need for individuals requiring long-term, time released delivery. The Company believes, subject to testing and trials to be initiated by our participating physicians, that the patch may able to deliver cannabinoids for up to 48 hours. The Company further expects that this mechanism of delivery could revolutionize the way cannabinoids are introduced into the blood stream minimizing the negative effects on lungs and other organs commonly seen in other delivery methods. The Company expects to be ready to begin trials in 90 days.

The Company intends to target a broad range of specialties with this novel product, including but not limited to sports medicine, pain management, neurology, and osteopathic medicine.

"Transdermal delivery of Cannabinoids has a global reach because diseases such as osteoporosis which affects about 52 million Americans and causes more than 8.9 million fractures worldwide annually, resulting in an osteoporotic fracture every 3 seconds, will greatly benefit from this method of delivery. It will ensure long term absorption on a continual basis in order to alleviate the targeted symptoms. Constant delivery of cannabinoids transdermally will also help to reduce pain and swelling in other medical conditions," states Medical Director, Dr. Vasthi Alvarez Avila.

ABOUT THE COMPANY

ProCannas core business focuses on the manufacture and distribution of new, pharmaceutical grade cannabinoid based products for medicinal use. Due to the concentrated strength and unique mix of ingredients integrated within our products, they are intended to be available to patients only through licensed participating physicians. Due to recent changes in the law regarding the medical use of marijuana, coupled with studies and a strong body of evidence highlighting that THC is not the significant component for medicinal use, doors are opening for innovation. Laws are expected to become even more favorable for companies like ProCannas.

Safe Harbor Statement:

This news release includes forward-looking statements pertaining to future anticipated projected plans, performance and developments, intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Any statements on this news release that are not statements of historical fact should be considered forward-looking statements. These forward-looking statements generally can be identified by phrases such as "believes," "expects," "anticipates," "foresees," "forecasts," "estimates," "intends," or other words or phrases of similar import. Similarly, statements in this news release that describe the Company's business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.